Evidence map›Paper›PMID 41280283›Full record

ReviewMetabolism open2025

Efficacy of

Sphesihle A L Mkhize, Wendy N Phoswa, Phikelelani S Ngubane, Kabelo Mokgalaboni

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Metabolism open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Antioxidants (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sphesihle A L MkhizeDepartment of Life and Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Florida Campus, Roodepoort, 1709, South Africa.
Wendy N PhoswaDepartment of Life and Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Florida Campus, Roodepoort, 1709, South Africa.
Phikelelani S NgubaneDepartment of Physiology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Westville Campus, Durban, 4001, South Africa.
Kabelo MokgalaboniDepartment of Life and Consumer Sciences, College of Agriculture and Environmental Sciences, University of South Africa, Florida Campus, Roodepoort, 1709, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of prediabetes is rising globally, and if untreated, it can lead to a surge in the rate of type 2 diabetes (T2D). Altogether, these conditions are characterised by hyperglycaemia, which promotes cardiovascular complications. Although Momordica has shown promising results in preclinical studies, the existing quantitative synthesis of evidence reports contradictory findings. This study aimed to evaluate the effect of

Indexed as

Bitter melonHyperglycaemiaMomordica charantiaPrediabetesType 2 diabetes

Identifiers

PMID41280283
PMCPMC12630335

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.